The founder team has extensive experience with research in academia and industry and shares a passionate determination to translate a vision into reality for improving glycoprotein drugs to the benefit of patients and society.
Claus Kristensen (CEO, Founder)
Claus Kristensen has a Ph.D. in human biology, and he brings extensive management experience from the biopharm industry in the development of CHO production cell lines (Novo Nordisk). Claus headed the development of 10 CHO cell lines for clinical trials including cell lines producing approved Factor8 and Factor9 products. He is responsible for running Glycodisplay operations and external contacts. Claus will serve on the board.
Henrik Clausen (Founder, Investor)
Professor Henrik Clausen is head of Center for Glycomics at University of Copenhagen. He is world renowned for research in Glycomics with more than 200 publications and over 40 issued US patents, and have experience in successful translational research and biotech start-ups. Henrik will serve on the board.
Zhang Yang (Founder)
Zhang Yang has a Ph.D. in biotechnology. He has been the driver of glycoengineering in mammalian cell lines, including the deconstructing of the N-glycosylation pathways in CHO cells. He has published a number of high-profile papers on genetic engineering of cells, and he is co-inventor of multiple patents and patent applications, including the glycoengineering of mammalian cells. Yang will be running Glycodisplay cell line engineering and display technologies.
Yoshiki Narimatsu (Founder)
Yoshiki Narimatsu has a Ph.D. in biology. He has In-depth hands-on knowledge of glycoengineering with particular focus on human cell lines. He is co-inventor of the GlycoDisplay technology. Yoshiki will be running Glycodisplay cell line engineering and display technologies.
Eric Paul Bennett (Founder, investor)
Eric Paul Bennett has a Dr.med. and MSc. in biochemistry. He is associate professor at Center for Glycomics at University of Copenhagen. He has long time experience in glycomics and targeted glycogene engineering in mammalian cells. He has published 100+ papers. Eric is a renowned expert and speaker on targeted gene editing technology and optimization of cell engineering technologies.